Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism

J Cyst Fibros. 2017 Jan;16(1):89-90. doi: 10.1016/j.jcf.2016.10.008. Epub 2016 Oct 31.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Aminophenols / therapeutic use*
  • Chloride Channel Agonists / therapeutic use*
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / genetics*
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
  • Humans
  • Male
  • Polymorphism, Genetic
  • Quinolones / therapeutic use*

Substances

  • Aminophenols
  • Chloride Channel Agonists
  • Quinolones
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • ivacaftor